RTOG 0825 [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

====== RTOG 0825 ======

Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
Protocol Documents
Principal Investigator: Mark R. Gilbert, MD
Primary Objective:

To determine whether the addition of bevacizumab to temozolomide and radiation improves efficacy as measured by progression-free and/or overall survival.
Patient Population:

Histopathologically confirmed glioblastoma (WHO Grade IV) confirmed by central pathology tissue screening  prior to step 2 registration. Tumor tissue that is determined by central pathology tissue screening prior to step 2 registration to be of sufficient size for analysis of MGMT status and determination of molecular profile. The tumor must have a supratentorial component.